Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK tax dispute

Executive Summary

GlaxoSmithKline receives Internal Revenue Service notice of deficiency for $1.9 bil. in taxes for years 1997-2000. "GSK disagrees with this tax claim, and the company believes that it has paid all the taxes owed to the U.S. government for these years," GSK said. The company received a separate notice of deficiency in 2004 for $2.7 bil. in taxes for 1989-1996 (1"The Pink Sheet" Jan. 12, 2004, p. 40). The claims are related to allocation of taxes on profits for heritage company Glaxo Wellcome products, GSK says. The company will ask U.S. tax court to consolidate 1997-2000 claim with case pending for the 1989-1996 tax years; a provisional trial date is set for October 2006. GSK estimates interest owed on the two claims would total $3.2 bil. net of federal tax relief if IRS is successful...

You may also be interested in...

GSK Contests $5.2 Bil. Tax Bill After IRS Decision On Zantac Transfer Pricing

GlaxoSmithKline and the Internal Revenue Service are headed to court over the IRS' conclusion that the company owes $5.2 bil. for unpaid taxes, penalty charges and interest

Canada Boosts Postmarket Device Safety With New Reporting Rules

Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.

Valneva Starts COVID-19 Vaccine Production In Scotland

Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts